M. D. Suprun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
M. D. Suprun has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Tatiana Valentinovna Beketova
V.A. Nasonova Research Institute of Rheumatology; Central State Medical Academy of the Administrative Directorate of the President of the Russian Federation; Moscow Polytechnic University
4 shared publications - V. V. Babak
V.A. Nasonova Research Institute of Rheumatology
4 shared publications - L. A. Semeyonova
V.A. Nasonova Research Institute of Rheumatology
2 shared publications - M. D. Evsikova
V.A. Nasonova Research Institute of Rheumatology
2 shared publications - Aleksander M. Lila
V.A. Nasonova Research Institute of Rheumatology; Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of the Russian Federation
1 shared publication - E. N. Kharlamova
V.A. Nasonova Research Institute of Rheumatology
1 shared publication
Latest Publications
- 24 June 2026
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 20 (3)
Ocular involvement in antineutrophil cytoplasmic antibody-associated vasculitis
- 24 June 2026
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 20 (3)
Ocular involvement in antineutrophil cytoplasmic antibody-associated vasculitis
- Open Access
- 31 August 2025
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 63 (4) , 407-414
Pseudothophus form of calcium pyrophosphate deposition disease: Features of diagnosis and course of the disease (description of a clinical case)
Calcium pyrophosphate deposition disease (CPPD) is a disease that occurs under the guise of various diseases and is characterized by a variety of clinical forms. One of the most rare and diagnostically difficult variants is chronic arthritis with the formation of periarticular deposits of calcium pyrophosphate crystals, imitating gouty tophi. The article presents a clinical case and analysis of the differential diagnosis of a patient with a pseudo-tophaceous form of CPPD.
- 31 August 2025
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 63 (4) , 407-414
Open AccessPseudothophus form of calcium pyrophosphate deposition disease: Features of diagnosis and course of the disease (description of a clinical case)
Calcium pyrophosphate deposition disease (CPPD) is a disease that occurs under the guise of various diseases and is characterized by a variety of clinical forms. One of the most rare and diagnostically difficult variants is chronic arthritis with the formation of periarticular deposits of calcium pyrophosphate crystals, imitating gouty tophi. The article presents a clinical case and analysis of the differential diagnosis of a patient with a pseudo-tophaceous form of CPPD.
- Open Access
- 20 February 2024
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 18 (1) , 76-83
Difficulties in the differential diagnosis of focal lung lesions in a patient with rheumatoid arthritis who has received anti-B-cell therapy with rituximab. Description of a clinical case
We present a clinical case of a patient treated with rituximab and methotrexate for rheumatoid arthritis with progressive focal lung lesions that were difficult to interpret. The complexity of the problem of focal lung lesions in rheumatic diseases, which involves a broad spectrum of clinical medical disciplines, is emphasized.
- 20 February 2024
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 18 (1) , 76-83
Open AccessDifficulties in the differential diagnosis of focal lung lesions in a patient with rheumatoid arthritis who has received anti-B-cell therapy with rituximab. Description of a clinical case
We present a clinical case of a patient treated with rituximab and methotrexate for rheumatoid arthritis with progressive focal lung lesions that were difficult to interpret. The complexity of the problem of focal lung lesions in rheumatic diseases, which involves a broad spectrum of clinical medical disciplines, is emphasized.
- Open Access
- 7 July 2022
- Published by PE Polunina Elizareta Gennadievna in Ophthalmology in Russia
- Vol. 19 (2) , 452-457
Ocular Manifestations of COVID-19 in a Patient with ANCAAssociated Vasculitis Treated with Rituximab. A Case Report
The World Health Organization announced a new coronavirus pandemic on 11 March 2020. It is known that the most frequent clinical manifestation of a new coronavirus infection is lung damage with the evolution of pneumonia, as well as respiratory distress syndrome. The highest risk of severe traction and death is known to occur in the immunosuppressive group of patients. These patients include rheumatologically patients. Currently, there is no complete understanding of the pathogenesis of the development of covid-19, as well as the pathogenesis of the development of autoimmune diseases. In a pandemic, the question of how the coronavirus infection proceeds in patients on immunosuppressive therapy, in particular on anti-B cell, is relevant. In our case report presents a 69-year-old female with ANCA-associated vasculitis remission having received a B-cell-depleting therapy with rituximab (RTX), who had an ocular lesion as a clinical manifestation of Coronavirus disease 2019 (COVID-19). Two months after RTX treatment, COVID-19 was diagnosed. The patient had extrapulmonary manifestations including central nervous system involvement and ocular symptoms such as conjunctivitis, without respiratory pathology. In this clinical observation, the patient’s disease manifested itself with right-sided conjunctivitis, which is a rare manifestation as the first symptom. This article describes the features of the course and outcome of the disease, as well as, the protective effect of RTX in course of COVID-19 is discussed. A comparative analysis of cases of COVID-19 with eye damage is being carried out. This clinical observation is of great value for doctors of all specialties, especially ophthalmologists. A multidisciplinary approach is crucial to manage COVID-19.
- 7 July 2022
- Published by PE Polunina Elizareta Gennadievna in Ophthalmology in Russia
- Vol. 19 (2) , 452-457
Open AccessOcular Manifestations of COVID-19 in a Patient with ANCAAssociated Vasculitis Treated with Rituximab. A Case Report
The World Health Organization announced a new coronavirus pandemic on 11 March 2020. It is known that the most frequent clinical manifestation of a new coronavirus infection is lung damage with the evolution of pneumonia, as well as respiratory distress syndrome. The highest risk of severe traction and death is known to occur in the immunosuppressive group of patients. These patients include rheumatologically patients. Currently, there is no complete understanding of the pathogenesis of the development of covid-19, as well as the pathogenesis of the development of autoimmune diseases. In a pandemic, the question of how the coronavirus infection proceeds in patients on immunosuppressive therapy, in particular on anti-B cell, is relevant. In our case report presents a 69-year-old female with ANCA-associated vasculitis remission having received a B-cell-depleting therapy with rituximab (RTX), who had an ocular lesion as a clinical manifestation of Coronavirus disease 2019 (COVID-19). Two months after RTX treatment, COVID-19 was diagnosed. The patient had extrapulmonary manifestations including central nervous system involvement and ocular symptoms such as conjunctivitis, without respiratory pathology. In this clinical observation, the patient’s disease manifested itself with right-sided conjunctivitis, which is a rare manifestation as the first symptom. This article describes the features of the course and outcome of the disease, as well as, the protective effect of RTX in course of COVID-19 is discussed. A comparative analysis of cases of COVID-19 with eye damage is being carried out. This clinical observation is of great value for doctors of all specialties, especially ophthalmologists. A multidisciplinary approach is crucial to manage COVID-19.
- Open Access
- 14 May 2022
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 60 (2) , 162-164
On the issue of post COVID-19 condition in patients with rheumatic diseases
Actual problems of rheumatology include the possibility of developing a wide range of long-term consequences of COVID-19, so-called post-COVID syndrome (PCS). The results of our own research are presented, during which among 45 patients over 18 years with rheumatic diseases (RD) PCS was detected in 20% cases: 6 of them had ANCAassociated vasculitis (AAV) and one each for rheumatoid arthritis, juvenile arthritis and osteoarthritis. In AAV cases PCS was more severe and varied than in other RD: lung lesions according to computed tomography (up to the damage 75% of the lung parenchyma), skin an d nervous (Guillain–Barré syndrome) lesions, myalgias, arthralgias were present. In most patients PCS ended in recovery, sudden death occurred only in the patient with AAV. The frequency of RD’s relapses in patients with PCS was 9%. Relapses were not noted in AAV, against the background of anti-B cell therapy with rituximab. Our own results and literature data indicate that patients with RD after COVID-19 need careful continuous monitoring to detect long-term complications of coronavirus infection and early diagnosis of relapses of the underlying disease.
- 14 May 2022
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 60 (2) , 162-164
Open AccessOn the issue of post COVID-19 condition in patients with rheumatic diseases
Actual problems of rheumatology include the possibility of developing a wide range of long-term consequences of COVID-19, so-called post-COVID syndrome (PCS). The results of our own research are presented, during which among 45 patients over 18 years with rheumatic diseases (RD) PCS was detected in 20% cases: 6 of them had ANCAassociated vasculitis (AAV) and one each for rheumatoid arthritis, juvenile arthritis and osteoarthritis. In AAV cases PCS was more severe and varied than in other RD: lung lesions according to computed tomography (up to the damage 75% of the lung parenchyma), skin an d nervous (Guillain–Barré syndrome) lesions, myalgias, arthralgias were present. In most patients PCS ended in recovery, sudden death occurred only in the patient with AAV. The frequency of RD’s relapses in patients with PCS was 9%. Relapses were not noted in AAV, against the background of anti-B cell therapy with rituximab. Our own results and literature data indicate that patients with RD after COVID-19 need careful continuous monitoring to detect long-term complications of coronavirus infection and early diagnosis of relapses of the underlying disease.
- Open Access
- 15 July 2021
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 59 (3) , 357-361-361
Granulomatosis with polyangiitis with severe lung involvement: efficacy of anti-B cell therapy with Rituximab
The present report illustrates efficacy of rituximab (RTX) in granulomatosis with polyangiitis (GPA) with severe lung involvement. Female patient, 45 years old, was ill since March 2016, her disease manifested at the onset with fever, recurrent epistaxis, otitis media, mastoiditis, conjunctivitis and arthritis. Thoracic CT scan showed multiple decaying pulmonary infiltrates. The presence of PR3-ANCA confirmed the diagnosis of GPA. Induction therapy included high doses of glucocorticoids, cyclophosphamide (total dose 4 g), with following azathioprine and mycophenolate mofetil. Lung disease continued to progress with emerging extensive infiltrates and forming a giant cavity with air-fluid level in the right lung. Further treatment included antibiotics followed by surgical draining of lung cavity in December 2018. Fever, necrotic rhinitis and otitis persisted despite treatment, lab findings included red blood cells in the urine, C-reactive protein 90 g/l, thrombocytosis 740×109/l, anemia (Hb 80 g/l). RTX 2 g and intravenous immunoglobulin were initiated in December 2018, a second course of RTX (0.5 g) was administered 4 months later. Patient’s condition was gradually improving, CT scan at 6 months after RTX treatment showed fibrous tissue in the area of former cavity. One year later, total RTX dose was 3.5 g, further regression of changes and GPA remission were achieved. There were no adverse reactions. Anti-B cell therapy with RTX is a safe and highly effective option in GPA patients with severe destructive lung disease, potentially curative even in cases of giant pulmonary cavities.
- 15 July 2021
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 59 (3) , 357-361-361
Open AccessGranulomatosis with polyangiitis with severe lung involvement: efficacy of anti-B cell therapy with Rituximab
The present report illustrates efficacy of rituximab (RTX) in granulomatosis with polyangiitis (GPA) with severe lung involvement. Female patient, 45 years old, was ill since March 2016, her disease manifested at the onset with fever, recurrent epistaxis, otitis media, mastoiditis, conjunctivitis and arthritis. Thoracic CT scan showed multiple decaying pulmonary infiltrates. The presence of PR3-ANCA confirmed the diagnosis of GPA. Induction therapy included high doses of glucocorticoids, cyclophosphamide (total dose 4 g), with following azathioprine and mycophenolate mofetil. Lung disease continued to progress with emerging extensive infiltrates and forming a giant cavity with air-fluid level in the right lung. Further treatment included antibiotics followed by surgical draining of lung cavity in December 2018. Fever, necrotic rhinitis and otitis persisted despite treatment, lab findings included red blood cells in the urine, C-reactive protein 90 g/l, thrombocytosis 740×109/l, anemia (Hb 80 g/l). RTX 2 g and intravenous immunoglobulin were initiated in December 2018, a second course of RTX (0.5 g) was administered 4 months later. Patient’s condition was gradually improving, CT scan at 6 months after RTX treatment showed fibrous tissue in the area of former cavity. One year later, total RTX dose was 3.5 g, further regression of changes and GPA remission were achieved. There were no adverse reactions. Anti-B cell therapy with RTX is a safe and highly effective option in GPA patients with severe destructive lung disease, potentially curative even in cases of giant pulmonary cavities.
- Open Access
- 3 March 2021
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 59 (1) , 37-46
The course and outcomes of COVID-19 in patients with ANCA-associated systemic vasculitis, receiving biological therapy (Rituximab, Mepolizumab): The results of the first 8 months of the pandemic
Течение и исходы COVID-19 у пациентов с АНЦА-ассоциированными системными васкулитами, получающих лечение генно-инженерными биологическими препаратами (ритуксимаб, меполизумаб): итоги первых 8 месяцев пандемии
- 3 March 2021
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 59 (1) , 37-46
Open AccessThe course and outcomes of COVID-19 in patients with ANCA-associated systemic vasculitis, receiving biological therapy (Rituximab, Mepolizumab): The results of the first 8 months of the pandemic
Течение и исходы COVID-19 у пациентов с АНЦА-ассоциированными системными васкулитами, получающих лечение генно-инженерными биологическими препаратами (ритуксимаб, меполизумаб): итоги первых 8 месяцев пандемии